Bridging Biomedical Engineering and Orthopaedic Surgery
Salnus is a biomedical AI company building deep learning-based pre-operative analysis and surgical planning tools for orthopaedic surgeons. Based in Istanbul, our team combines peer-reviewed research with production-grade software engineering under one roof.
TEAM
Burak Serteser
CEO & Founder · Biomedical Engineer, MSc.
With an academic background in biomedical engineering, Burak leads Salnus's research and product development in orthopaedic surgical planning and AI applications. He has peer-reviewed publications on patient-specific instrumentation (PSI) and deep learning-based osteoarthritis analysis.
PEER-REVIEWED RESEARCH
Clinical Validation of 3D-Printed Patient-Specific Instrumentation for Knee Reconstruction
The Orthopaedic Journal of Sports Medicine (OJSM)
Read Details →Deep Learning-Based Automated Grading Tool for Knee Osteoarthritis
Clinical validation in progress · Original Article
RESEARCH & CLINICAL COLLABORATION
Salnus collaborates with clinicians and academic researchers on dataset curation, algorithm validation, and peer-reviewed publication; our 2026 OJSM study is one example. Pilot deployments run under confidentiality, and clinical references are available on request.
For clinical or academic collaboration, contact our team.
COMPANY INFO
FREQUENTLY ASKED QUESTIONS
What is Salnus?
Salnus is a software-only, implant-agnostic, research-use-only (RUO) orthopaedic AI platform for preoperative surgical planning and clinical decision support. It covers knee osteoarthritis assessment, patient-specific surgical guides, and 3D planning on a DICOM pipeline.
Is Salnus FDA or CE cleared?
No. All Salnus products are research-use-only (RUO) and are not cleared or approved medical devices. Salnus has not claimed or received FDA, CE, or other regulatory clearance, and is not affiliated with companies such as Salus, Formus Labs, or PeekMed.
What does research-use-only (RUO) mean?
RUO means the software is intended for research and evaluation, not for clinical diagnosis or treatment decisions on individual patients. Regulatory clearance (CE marking, TITCK registration) is on the roadmap and has not yet been obtained.
Who founded Salnus?
Salnus was founded in 2022 in Istanbul by Burak Serteser, a biomedical engineer (not a physician) and co-author of a 2026 peer-reviewed study in the Orthopaedic Journal of Sports Medicine (OJSM), DOI 10.1177/23259671261417360.
How is Salnus different from other orthopaedic planning tools?
Salnus is implant-agnostic rather than tied to a single manufacturer, software-only with no hardware or capital cost, and runs in the browser with client-side DICOM processing, so patient images need not leave the clinic.
What evidence supports Salnus?
A peer-reviewed 2026 OJSM publication (DOI 10.1177/23259671261417360) on 3D-printed patient-specific guides, alongside internal validation work including a four-bone knee CT segmentation model (167 patients; Dice 0.964; manuscript in submission).
MISSION
To build privacy-first, peer-reviewed AI tools that support orthopaedic surgeons with pre-operative analysis and planning. All our AI inference runs client-side, patient data never reaches our servers.